These results indicate a potential risk in the use of semaglutide in patients with NENs expressing GLP-1 receptors
For practitioners who may be concerned about the evolving regulatory landscape around compounded medications, energetic therapies provide a proven, compliant option that supports patient outcomes without legal complications
Moreover, the levels of a specific kidney function marker, 2-microglobulin, decreased significantly
and too few clinicians trained in obesity medicine, Saunders told Healio | Endocrine Today
A double-blind, randomized, clinical trial of the effect of vitamin A and zinc supplementation on diarrheal disease and respiratory tract infections in children in Mexico City, Mex Fritz, H., Kennedy, D., Fergusson, D., Fernandes, R., Doucette, S., Cooley, K., Seely, A., Sagar, S., Wong, R., and Seely, D
Note: an older GLP-1, liraglutide (Saxenda) , is also approved for weight management but is being discontinued as newer options take over